Opioid REMS-Compliant Accredited CE Activities — 2020 Update

ACCME Highlights (09/21/20)

A new report from the Accreditation Council for Continuing Medical Education (ACCME) updates the scope of continuing education (CE) activities complying with the Food and Drug Administration's (FDA) Risk Evaluation and Mitigation Strategies (REMS) on opioid analgesics. The 2020 update concerns the Opioid Analgesic REMS (OA REMS) program, a 2018 expansion of the Extended-Release and Long-Acting Opioid Analgesics REMS. The report indicates that 24 accredited providers reported 213 OA REMS-compliant CE activities from March 1, 2020, through Aug. 15, 2020. Of those, 166 activities had been held or issued, with 44 more planned for the future. Most of those activities were offered as live courses, and accredited providers reported 111,358 learners for activities that had been held or released. Of these participants, 57% said they were registered to prescribe Schedule 2 or 3 drugs. Roughly 82% reported having an individual license and 18% said they had an institutional license. Physicians and advanced practice nurses formed the largest concentrations of learners who completed the CE activities.

Read More

Recent Stories
An Examination of State and Federal Opioid Analgesic and Continuing Education Policies: 2016–2018

Commission Meets to Offer Input on Task Force Work To-Date

From the Editor: “V” Is for Virtual (and Sometimes Not Victory)